Poland, along with Hungary, Spain, Italy, and Russia, is ranked in the top 20 most attractive corporate investment destinations for companies from the life sciences sector, i.e., biotechnology, genetics, pharmacy, according to a report published on Monday by Colliers.
The EMEA (Europe, Middle East, and Africa) region reported a 72 percent increase in life sciences corporate investment in 2020, according to a Colliers report. Since 2010, $81.5bn has been invested in the region within the sector.
According to Colliers Poland, next to Hungary, Spain, Italy, and Russia is a country that ranks among the top 20 most attractive locations for corporate investments of companies from the life sciences sector. In each country, their value has exceeded $1bn over the past decade, was written in the report.
Contributing to the growth of the sector was the coronavirus pandemic, which strengthened the business activities of companies in the segment, raising demand for real estate, among others.
As noted, since 2010, the majority of life sciences investments were related to medical device and drug manufacturing (59 percent of all capital investments), as well as research and development (11.4 percent).